Drug Type Small molecule drug |
Synonyms DSP 5336, DSP-5336 |
Target |
Mechanism menin inhibitors(Menin inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
RegulationOrphan Drug (US), Fast Track (US) |
Molecular FormulaC33H43FN6O3 |
InChIKeyJQHJEDMMWUIYCE-FVVBACEJSA-N |
CAS Registry2412555-70-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Lymphoblastic Leukemia | Phase 2 | US | 28 Feb 2022 | |
Acute Lymphoblastic Leukemia | Phase 2 | JP | 28 Feb 2022 | |
Acute Lymphoblastic Leukemia | Phase 2 | BE | 28 Feb 2022 | |
Acute Lymphoblastic Leukemia | Phase 2 | CA | 28 Feb 2022 | |
Acute Lymphoblastic Leukemia | Phase 2 | FR | 28 Feb 2022 | |
Acute Lymphoblastic Leukemia | Phase 2 | IT | 28 Feb 2022 | |
Acute Lymphoblastic Leukemia | Phase 2 | SG | 28 Feb 2022 | |
Acute Lymphoblastic Leukemia | Phase 2 | KR | 28 Feb 2022 | |
Acute Lymphoblastic Leukemia | Phase 2 | ES | 28 Feb 2022 | |
Acute Lymphoblastic Leukemia | Phase 2 | TW | 28 Feb 2022 |
NCT04988555 (EHA2024) Manual | Phase 1/2 | acute leukemia NPM1 Mutation | KMT2A Rearrangement | 58 | senuydduxz(zbiqjjkcni) = cojwxifrcf sggjugixon (hgayiftgou ) View more | Positive | 14 May 2024 | |
NCT04988555 (ASH2023) Manual | Phase 1/2 | 24 | DSP-5336±concomitant azole therapy | plrogprwqi(mwvzvbwltn) = lvsqimnnxo fmmemudhul (qeixtjcrhi ) View more | Positive | 10 Dec 2023 | |
DSP-5336±concomitant azole therapy (NPM1c) | sxkjmyjmlh(uupsbocnjt) = jjhzomhsnn vloqqoriuu (eaqxvnziej ) |